Pharmacokinetic-Modifying Linker Design Modulates Performance of Multivalent PSMA/GRPR-Cell-Targeting 177Lu Radiopharmaceuticals
Authors:
- Claudia G. ChambersCCClaudia G. Chambers
- Grace LilesGLGrace Liles
- Anupam MathurAMAnupam Mathur
- Tamer M. SakrTSTamer M. Sakr
- John M. HimmelbergJHJohn M. Himmelberg
- Fabio GallaziFGFabio Gallazi
- Lisa WatkinsonLWLisa Watkinson
- Terry CarmackTCTerry Carmack
- Yue GuanYGYue Guan
- Susan RottinghausSRSusan Rottinghaus
- Yubin MiaoYMYubin Miao
- Christine LovingierCLChristine Lovingier
Open Access
Abstract
Background/Objectives: A series of PSMA/GRPR-targeting compounds were selected based on modifications to their respective pharmacokinetic-modifying linking groups and the structure of the PSMA-binding moiety, to examine how these alterations impact binding affinity and specificity for preclinical prostate cancer models. Methods: The multi-receptor targeting heterodimers PSMA/2PSMA-X-DOTA-Y-BBN (where X is 6-aminohexanoic acid (6AHX) or polyethylene glycol-4 (PEG4) and Y is either 8-aminooctanoic acid (8AOC) or carboxy piperidine (CP)) were radiolabeled with the theranostic isotope [177Lu]Lu. Each heterodimer construct was evaluated through characterization, stability, whole-cell in vitro studies, biodistribution in tumor-bearing mice, and in vivo small animal SPECT/CT molecular imaging. Results: In vitro evaluation of 2PSMA-6AHX-DOTA-8AOC-BBN demonstrated moderate IC50 values of 200 ± 20 nM in LNCaP cells and 21 ± 1 nM in PC3 cells. Subsequent biodistribution studies demonstrated selective tumor uptake at 4 h post-intravenous injection with uptake of 9.52 ± 2.59%ID/g in GRPR[+] PC3 tumors and 6.37 ± 0.64%ID/g in PSMA[+] PC3-PIP tumors. At 24 h post-injection, high tumor-to-blood ratios (874.0 ± 276 in PC3 and 344.3 ± 85 in PC3-PIP) and tumor-to-muscle ratios (739.8 ± 277 in PC3 and 403.5 ± 66 in PC3-PIP) were observed, further supporting the theranostic feasibility of the radiolabeled heterodimer. Small animal SPECT/CT imaging confirmed tumor targeting specificity of the heterobivalent peptide. Conclusions: Evaluation in PSMA/GRPR-expressing tumor models identified 2PSMA-6AHX-DOTA-8AOC-BBN as a leading candidate, having enhanced tumor uptake and favorable pharmacokinetics in tumor-bearing mice. These investigations advance structure–activity relationship understanding and support heterobivalent radiopharmaceuticals for precision imaging and targeted prostate cancer therapy.Keywords
Funding Information
- U.S. Department of Veterans Affairs (I01-BX000964)
- U.S. Department of Veterans Affairs (IK6BX006810)
This publication has 66 references indexed in Scilit:
- An Overview of Structural Framework and Classification of Theranostic RadiopharmaceuticalsChemistrySelect, 2024
- Elevating theranostics: The emergence and promise of radiopharmaceutical cell‐targeting heterodimers in human cancersiRADIOLOGY, 2024
- Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical modelJournal of Pharmacokinetics and Pharmacodynamics, 2023
- Linker Hydrophilicity Modulates the Anticancer Activity of RGD–Cryptophycin ConjugatesChemistry – A European Journal, 2020
- Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Radiolabeled Heterobivalent Peptidic Ligands: an Approach with High Future Potential for in vivo Imaging and Therapy of Malignant DiseasesChemMedChem, 2013
- Improved targeting of the αvβ3 integrin by multimerisation of RGD peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Measurement of Glutamate Carboxypeptidase II (NAALADase) Enzyme Activity by the Hydrolysis of [3H]‐N‐Acetylaspartylglutamate (NAAG)Current Protocols in Pharmacology, 2001
- Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)The Prostate, 1991